Prevalence and Incidence in patients with fibrosing ILD in Japan - A National Database Study

Prevalence and Incidence in patients with fibrosing ILD in Japan - A National Database Study - Epidemiology of ILD in Japan (NDB study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059745

Enrollment

200000

Registered

2025-12-01

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IPF, PPF, and non-progressive ILD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with at least 2 fibrosing ILD codes in different months during the patient identification period Patients aged 20 years or older on the index date Patients for whom data for the 12 months prior to the index date can be extracted as baseline data

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To investigate the prevalence (per 100,000 people) and incidence (per 100,000 person-years) of IPF, PPF, and non-progressive ILD by calendar year in Japan.	—

Secondary

Measure	Time frame
To investigate patient characteristics in patients with IPF, PPF, and non-progressive ILD in Japan. To investigate mortality in patients with IPF, PPF, and non-progressive ILD by calendar year in Japan. To investigate the proportion of each clinical ILD diagnosis in patients with PPF and non-progressive ILD in Japan. To investigate the proportion of patients with PPF among patients with fibrosing ILD in each clinical ILD diagnosis in Japan. To investigate patient characteristics in each clinical ILD diagnosis of patients with PPF and non-progressive ILD in Japan. To investigate the distribution of PPF progression proxies met in patients with progression to PPF and the number of individuals meeting each criterion in Japan. Exploratory objective: To describe the proportions of patients with chronic cough among those with IPF, PPF, and non-progressive ILD in Japan.	—

Measure

Time frame

To investigate patient characteristics in patients with IPF, PPF, and non-progressive ILD in Japan. To investigate mortality in patients with IPF, PPF, and non-progressive ILD by calendar year in Japan. To investigate the proportion of each clinical ILD diagnosis in patients with PPF and non-progressive ILD in Japan. To investigate the proportion of patients with PPF among patients with fibrosing ILD in each clinical ILD diagnosis in Japan. To investigate patient characteristics in each clinical ILD diagnosis of patients with PPF and non-progressive ILD in Japan. To investigate the distribution of PPF progression proxies met in patients with progression to PPF and the number of individuals meeting each criterion in Japan. Exploratory objective: To describe the proportions of patients with chronic cough among those with IPF, PPF, and non-progressive ILD in Japan.

—

Countries

Japan

Contacts

Public ContactTakao Hanada

Nippon Boehringer Ingelheim Co., Ltd. Medicine Division

takao.hanada@boehringer-ingelheim.com03-6417-2794

Outcome results